Tencent Music(TME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TME Tencent Music

Trading 05-03 13:16:33 EDT

13.39

+0.34

+2.61%

High13.45	Low12.96	Vol4.31M
Open13.05	D1 Closing13.05	Amplitude3.75%
Mkt Cap22.98B	Tradable Cap9.48B	Total Shares1.72B
T/O57.18M	T/O Rate0.61%	Tradable Shares708.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TME","market":"US","secType":"STK","nameCN":"Tencent Music","latestPrice":13.39,"timestamp":1714756592801,"preClose":13.05,"halted":0,"volume":4307677,"delay":0,"floatShares":708000000,"shares":1716077130,"eps":0.43718,"marketStatus":"Trading","change":0.34,"latestTime":"05-03 13:16:33 EDT","open":13.045,"high":13.45,"low":12.96,"amount":57177769.737066,"amplitude":0.037548,"askPrice":13.39,"askSize":705,"bidPrice":13.38,"bidSize":2016,"shortable":3,"etf":0,"ttmEps":0.43718,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1714766400000},"marketStatusCode":2,"adr":0,"adrRate":2,"listingDate":1544590800000,"exchange":"NYSE","adjPreClose":13.05,"preHourTrading":{"tag":"盘前","latestPrice":13.05,"preClose":13.05,"latestTime":"09:28 EDT","volume":2116,"amount":27641.2551,"timestamp":1714742921550},"postHourTrading":{"tag":"盘后","latestPrice":13.08,"preClose":13.05,"latestTime":"19:51 EDT","volume":76189,"amount":994394.765,"timestamp":1714693869496},"volumeRatio":1.213806},"requestUrl":"/m/hq/s/TME/","defaultTab":"news","newsList":[{"id":"2432672240","title":"Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672240","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432672240?lang=en_us&edition=fundamental","pubTime":"2024-05-02 12:00","pubTimestamp":1714622400,"startTime":"0","endTime":"0","summary":"Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six pati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874149/0/en/Positive-Initial-Clinical-Data-Reported-from-Immutep-s-Efti-Combined-with-Radiotherapy-and-Checkpoint-Inhibitor-from-Phase-II-Trial-in-Soft-Tissue-Sarcoma.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432524953","title":"Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432524953","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432524953?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:00","pubTimestamp":1714561200,"startTime":"0","endTime":"0","summary":"Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSCLC Patients with Brain Metastases. Board of Directors Strengthened with the Addition of Dr. Mostafa Ronaghi. Updated Guidance of Cash Runway for Operations through Q1 2025. MIAMI, May 01, 2024----Summit Therapeutics Inc.   today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data. Notably, in patients with first line advanced or metastatic squamous NSCLC without actionable genomic alterations , a median PFS  of 11.1 months  was observed; median overall survival  was not yet reached after a median follow-up time of 22.1 months. Additionally, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R2IOUMBbGxRVKEGi3cNe1A--~B/aD0zMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4eff5eb83aa778fdab40fa8e7ef1470c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R2IOUMBbGxRVKEGi3cNe1A--~B/aD0zMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4eff5eb83aa778fdab40fa8e7ef1470c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/summit-therapeutics-reports-financial-results-110000627.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431855736","title":"INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2431855736","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431855736?lang=en_us&edition=fundamental","pubTime":"2024-04-29 12:00","pubTimestamp":1714363200,"startTime":"0","endTime":"0","summary":"Boca Raton, Florida, April  29, 2024  (GLOBE NEWSWIRE) -- INmune Bio, Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871192/0/en/INmune-Bio-Inc-Completes-First-Cohort-and-Initiates-Second-Cohort-of-Phase-1-2-Study-of-INKmune-Natural-Killer-Cell-Therapy-in-Patients-with-Metastatic-Castration-Resistant-Prostat.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430236015","title":"Baron New Asia Fund Q1 2024 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2430236015","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430236015?lang=en_us&edition=fundamental","pubTime":"2024-04-26 00:20","pubTimestamp":1714062000,"startTime":"0","endTime":"0","summary":"Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing.Baron New Asia Fund gained 6.36% (Ins","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335295283/image_1335295283.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335295283/image_1335295283.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686176-baron-new-asia-fund-q1-2024-shareholder-letter","is_publish_highlight":false,"gpt_icon":0},{"id":"2430126235","title":"Press Release: TME Pharma Publishes 2023 Financial Results and Provides Operating Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2430126235","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2430126235?lang=en_us&edition=fundamental","pubTime":"2024-04-26 00:00","pubTimestamp":1714060800,"startTime":"0","endTime":"0","summary":"--  Financial highlights include successful public rights offering and the. subsequent 2024 buyback of all convertible bonds, terminating the. NOX-A12 GLORIA brain cancer trial nears completion with exceptional. --  NOX-A12 in combination with bevacizumab and radiotherapy delivers very. --  FDA clears Investigational New Drug  applications for NOX-A12. --  Fast Track Designation from FDA granted to NOX-A12 in brain cancer. Glioblastoma is a highly aggressive and deadly form of brain cancer. Patients with glioblastoma that is resistant to standard of care chemotherapy  and whose tumors are not amenable to complete surgical removal face a devastating prognosis of median overall survival  of approx. 10 months on standard of care. The development of effective treatments for these patients -- TME Pharma's target population in the GLORIA trial -- is particularly challenging since these tumo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2430807412","title":"Baron Emerging Markets Fund Q1 2024 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2430807412","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430807412?lang=en_us&edition=fundamental","pubTime":"2024-04-25 23:15","pubTimestamp":1714058100,"startTime":"0","endTime":"0","summary":"Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing.Baron Emerging Markets Fund gained 2.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323375651/image_1323375651.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323375651/image_1323375651.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686141-baron-emerging-markets-fund-q1-2024-shareholder-letter","is_publish_highlight":false,"gpt_icon":1},{"id":"2430495516","title":"Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2430495516","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430495516?lang=en_us&edition=fundamental","pubTime":"2024-04-25 04:30","pubTimestamp":1713990600,"startTime":"0","endTime":"0","summary":"MIAMI, April 24, 2024----Summit Therapeutics Inc.   will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website.Ivonescimab, known as SMT112 in Summit’s license territories, the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, is an investigational, novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays differentiated cooperative binding with each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.HARMONi-3 is a Phase III clinical t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8jMJRxUtygM8VrDgSNv_jA--~B/aD0zMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f19745c53dd415731d60e4481a86d1d5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8jMJRxUtygM8VrDgSNv_jA--~B/aD0zMDc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f19745c53dd415731d60e4481a86d1d5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/summit-therapeutics-host-first-quarter-203000635.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1136612440","title":"Hot Chinese ADRs Gain As Goldman Sachs, UBS Forecast Lift for Chinese Stocks From Market Reforms","url":"https://stock-news.laohu8.com/highlight/detail?id=1136612440","media":"Tiger Newspress","top":-1,"share":"https://ttm.financial/m/news/1136612440?lang=en_us&edition=fundamental","pubTime":"2024-04-24 21:49","pubTimestamp":1713966549,"startTime":"0","endTime":"0","summary":"China’s push to reshape its capital markets is set to give stock valuations a significant boost, according to Goldman Sachs. UBS Group joined the chorus by upgrading its recommendations on Hong Kong-l","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2429173075","title":"Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429173075","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429173075?lang=en_us&edition=fundamental","pubTime":"2024-04-24 09:27","pubTimestamp":1713922020,"startTime":"0","endTime":"0","summary":"Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors. SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical , a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement  with MSD .Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, 'BH3120', in combination with MSD's anti-PD-1 therapy, KEYTRUDA , in patients with progressive or metastatic solid tumors. Hanmi Pharmaceutical will sponsor the clinical trial, and MSD will supply KEYTRUDA.'BH3120' is a next-generation immunotherapy drug that applies 'Pentambody', a bispecific antibody platform technology, currently under join","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23105007","is_publish_highlight":false,"gpt_icon":0},{"id":"1110234046","title":"Hot Chinese ADRs Gain With Alibaba up Nearly 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110234046","media":"Tiger Newspress","top":-1,"share":"https://ttm.financial/m/news/1110234046?lang=en_us&edition=fundamental","pubTime":"2024-04-23 22:36","pubTimestamp":1713883015,"startTime":"0","endTime":"0","summary":"Hot Chinese ADRs gained in morning trading, following the trend of the overall market. Alibaba rose nearly 3%; PDD Holdings, JD.com, NIO and XPeng rose 2%; iQiyi rose 6%; Tencent Music rose 3%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2429115130","title":"Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment","url":"https://stock-news.laohu8.com/highlight/detail?id=2429115130","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429115130?lang=en_us&edition=fundamental","pubTime":"2024-04-23 22:32","pubTimestamp":1713882720,"startTime":"0","endTime":"0","summary":"Aubex Therapeutics Inc., a pioneering biotechnology firm, today announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment .Aubex’s R&D program shows promise, particularly in cancers where fibrosis drives progression, such as HER2+ and triple-negative  breast cancers, pancreatic cancer, esophageal squamous cell carcinoma , colon cancer, and non-small cell lung cancer. These solid tumors are notable for their pronounced fibrotic response, which impedes effective immune responses.Jeffrey A. Glazer expressed his excitement about the company's mission, stating, \"Aubex Therapeutics is thrilled to launch with a unique R&D program addressing the TME. This innovative program demonstrates promising early activity in altering ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23101205","is_publish_highlight":false,"gpt_icon":0},{"id":"2429715807","title":"TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2429715807","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429715807?lang=en_us&edition=fundamental","pubTime":"2024-04-23 14:00","pubTimestamp":1713852000,"startTime":"0","endTime":"0","summary":"Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival since the start of therapy. This survival compares favorably to the 5% survival rate at 2 years in the standard of care reference cohort. Final median overall survival rate for this NOX-A12 cohort reached an unprecedented 19.9 months, nearly doubling the 10.5 months mOS rate demonstrated by the standard of care reference cohort. GLORIA survival data supported recently announced FDA clearance of IND application for Phase 2 study in glioblastoma and award of Fast Track designation. \"This positive update from the GLORIA trial underlines the exceptional survival achieved by this cohort of patients with measurable tumors after surgery that are resistant to standard of care chemotherapy and gives more support for the potential of this NOX-A12 treatment regimen to prolong survival while preserving quality of life in patients suffering from this aggressive adult brain cancer,\" said","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23098333","is_publish_highlight":false,"gpt_icon":0},{"id":"1196650995","title":"Hot Chinese ADRs Gain With PDD Holdings and JD.com up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196650995","media":"Tiger Newspress","top":-1,"share":"https://ttm.financial/m/news/1196650995?lang=en_us&edition=fundamental","pubTime":"2024-04-22 22:30","pubTimestamp":1713796200,"startTime":"0","endTime":"0","summary":"Hot Chinese ADRs jumped in morning trading. Alibaba rose 1.7%; PDD Holdings, JD.com and Bilibili rose 4%; iQiyi and Tencent Music rose 2%.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":0},{"id":"2429714609","title":"Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2429714609","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2429714609?lang=en_us&edition=fundamental","pubTime":"2024-04-22 17:10","pubTimestamp":1713777000,"startTime":"0","endTime":"0","summary":"-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/22/2867122/0/en/Intratumoral-Injection-of-Phio-s-PH-762-significantly-inhibits-tumor-growth-in-murine-tumor-models-and-may-generate-memory-specific-T-cells.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429912045","title":"Tencent shares soar on early release of hotly anticipated mobile game","url":"https://stock-news.laohu8.com/highlight/detail?id=2429912045","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429912045?lang=en_us&edition=fundamental","pubTime":"2024-04-22 16:53","pubTimestamp":1713775980,"startTime":"0","endTime":"0","summary":"Shares of Tencent Holdings Ltd. saw their biggest one-day gain in nearly a year on news the Chinese tech giant plans an earlier release of a hotly anticipated mobile video game.Tencent  will release \"Dungeon and Fighter: Origin\" game on May 21, the game's developer, Korean-based Nexon Games  said in a press release. DNF, originally a computer game launched in 2005, has more than 850 million registered players worldwide, with gross revenue to date over $22 billion, said Nexon.\"Based on the enthusiastic player response to the Beta Test we offered earlier this year, and the strong marketing campaign planned by Tencent, we strongly believe Dungeon&Fighter Mobile can energize our large base of existing fans and attract new players to the franchise,\" said Junghun Lee, president and CEO of Nexon.Tencent had said in March that it would fast track the game after positive test results, with aims for a second quarter launch.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428329626","title":"Analysts Are Updating Their Tencent Music Entertainment Group (NYSE:TME) Estimates After Its Full-Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2428329626","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2428329626?lang=en_us&edition=fundamental","pubTime":"2024-04-20 20:25","pubTimestamp":1713615930,"startTime":"0","endTime":"0","summary":"As you might know, Tencent Music Entertainment Group  recently reported its full-year numbers. Tencent Music Entertainment Group reported CN28b in revenue, roughly in line with analyst forecasts, although statutory earnings per share  of CN3.11 beat expectations, being 2.8% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Tencent Music Entertainment Group after the latest results.Check out our latest analysis for Tencent Music Entertainment Group. The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. On the plus","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ff24jEG6fJ_mnhJ0xYBRaA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fbcb1fb47846c704491b7cdca16e4528","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ff24jEG6fJ_mnhJ0xYBRaA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fbcb1fb47846c704491b7cdca16e4528"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-updating-tencent-music-entertainment-122530107.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428544645","title":"Tencent Music Faces AI Integration Challenges Amidst New Regulatory Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2428544645","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428544645?lang=en_us&edition=fundamental","pubTime":"2024-04-20 14:01","pubTimestamp":1713592909,"startTime":"0","endTime":"0","summary":"Tencent Music Entertainment (TME) has disclosed a new risk, in the Regulation category. Tencent Music Entertainment’s integration of AI into its of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tencent-music-faces-ai-integration-challenges-amidst-new-regulatory-landscape?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tencent-music-faces-ai-integration-challenges-amidst-new-regulatory-landscape?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428291528","title":"Tencent Music Files 2023 Annual Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2428291528","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428291528?lang=en_us&edition=fundamental","pubTime":"2024-04-19 05:27","pubTimestamp":1713475653,"startTime":"0","endTime":"0","summary":"Tencent Music Entertainment (TME) has released an update. Tencent Music Entertainment Group, a leader in China’s online music and audio entertainme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tencent-music-files-2023-annual-financial-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tencent-music-files-2023-annual-financial-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428474905","title":"Tencent Music Entertainment Group Filed 2023 Annual Report on Form 20-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2428474905","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2428474905?lang=en_us&edition=fundamental","pubTime":"2024-04-19 04:50","pubTimestamp":1713473400,"startTime":"0","endTime":"0","summary":"SHENZHEN, China, April 18, 2024 /PRNewswire/ -- TencentMusic Entertainment Group  , the leading online music and audio entertainment platform inChina, today announced that it has filed its annual report on Form 20-F that includes its audited financial statements for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission  on April 18, 2024, U. S. Eastern Time.Investor Relations ContactTencent Music Entertainment Groupir@tencentmusic.com +86  8601-3388 ext. 818415","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z.bTrXlZo60.GOWA9rZLfQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4ebb33b789271cf5968b49f605725b2c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z.bTrXlZo60.GOWA9rZLfQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/4ebb33b789271cf5968b49f605725b2c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tencent-music-entertainment-group-filed-205000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tencent-music-entertainment-group-filed-205000655.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428653692","title":"Tencent Music: A Harmonious Future with Robust Subscriber and Ad Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2428653692","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428653692?lang=en_us&edition=fundamental","pubTime":"2024-04-18 13:05","pubTimestamp":1713416755,"startTime":"0","endTime":"0","summary":"Analyst Wei Fang from Mizuho Securities maintained a Buy rating on Tencent Music Entertainment Group (TME – Research Report) and increased the pric...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tencent-music-a-harmonious-future-with-robust-subscriber-and-ad-revenue-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tencent-music-a-harmonious-future-with-robust-subscriber-and-ad-revenue-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tencentmusic.com","stockEarnings":[{"period":"1week","weight":0.0292},{"period":"1month","weight":0.1569},{"period":"3month","weight":0.4404},{"period":"6month","weight":0.7423},{"period":"1year","weight":0.8432},{"period":"ytd","weight":0.4484}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tencent Music Entertainment Group operates online music entertainment platforms to provide music streaming, online karaoke, and live streaming services in the People's Republic of China. It offers QQ Music, Kugou Music, and Kuwo Music that enable users to discover music in personalized ways; and WeSing, which enables users to sing from its library of karaoke songs and share their performances in audio or video formats with friends. The company also operates QQ Music, Kugou Music, Kuwo Music, WeSing, Kugou Live, and Kuwo Live that provides an interactive online stage for performers and users to showcase their talent and engage with a diverse audience base; and Lazy Audio, an audio platform. In addition, it sells music-related merchandise, including Kugou headsets, smart speakers, WeSing karaoke microphones, and Hi-Fi systems; and offers online music event ticketing services, as well as services to smart device and automobile makers to build and operate music services on devices and vehicles. The company is based in Shenzhen, China. Tencent Music Entertainment Group is a subsidiary of Tencent Holdings Limited.","yearOnYearQuotes":[{"month":1,"riseRate":0.833333,"avgChangeRate":0.09218},{"month":2,"riseRate":0.333333,"avgChangeRate":0.002138},{"month":3,"riseRate":0.5,"avgChangeRate":-0.049853},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.029367},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.039065},{"month":6,"riseRate":0.8,"avgChangeRate":0.084362},{"month":7,"riseRate":0.2,"avgChangeRate":-0.076062},{"month":8,"riseRate":0.2,"avgChangeRate":-0.014757},{"month":9,"riseRate":0,"avgChangeRate":-0.108946},{"month":10,"riseRate":0.8,"avgChangeRate":0.040494},{"month":11,"riseRate":0.6,"avgChangeRate":0.210645},{"month":12,"riseRate":0.6,"avgChangeRate":0.057019}],"exchange":"NYSE","name":"Tencent Music","nameEN":"Tencent Music"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tencent Music(TME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tencent Music(TME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tencent Music,TME,Tencent Music股票,Tencent Music股票老虎,Tencent Music股票老虎国际,Tencent Music行情,Tencent Music股票行情,Tencent Music股价,Tencent Music股市,Tencent Music股票价格,Tencent Music股票交易,Tencent Music股票购买,Tencent Music股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tencent Music(TME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tencent Music(TME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction